14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today EXEL ranks #16097 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$15.84 (-3.88%)

Volume: 2M

Closed: Dec 03, 2021

Hollow Logo Score: -5.088

Exelixis Stock Forecast

$15.84 (-3.88%)

Volume: 2M

Closed: Dec 03, 2021

Score Hollow Logo -5.088
Which way will EXEL go? Request
Key Stats
P/E Ratio 30.51
Beta 0.75
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Exelixis stock currently holds an RSI14 at 22 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Exelixis stock downgraded to Strong Sell Candidate
(Updated on Dec 03, 2021)


Sell candidate since 2021-12-03

The Exelixis stock price fell by -3.88% on the last day (Friday, 3rd Dec 2021) from $16.48 to $15.84. During the day the stock fluctuated 5.91% from a day low at $15.74 to a day high of $16.67. The price has fallen in 6 of the last 10 days and is down by -9.43% for this period. Volume has increased on the last day by 1 million shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $38.68 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $15.70 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -15.69% during the next 3 months and, with a 90% probability hold a price between $13.24 and $17.30 at the end of this 3-month period.

Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Exelixis stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $16.71 and $19.16. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 02, 2021, and so far it has fallen -27.61%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.93 between high and low, or 5.91%. For the last week, the stock has had a daily average volatility of 3.98%.

Exelixis is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Exelixis stock A Buy?

Exelixis holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.088

Predicted Opening Price for Exelixis of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$16.08 $15.84 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 03, 2021 "HC Wainwright" gave "$65.00 - $52.00" rating for EXEL. The price target was changed from $19.42 to 11.2%.

Volatility and Risk
Daily Average Volatility: 3.98 %
Overall Risk: Very High High Medium Low Very Low
Volatility
3.98 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $18.10
Price: $15.84
No Support Found

EXEL Insider Trading Show all Trades

INSIDER POWER

0.717

Last 100 transactions
Buy: 1 481 300 | Sell: 2 066 049 (Shares)
Date Action Amount Person Type
Nov 24, 2021 Sell 17 236 Haley Patrick J. Common Stock
Nov 19, 2021 Sell 20 000 Feldbaum Carl B Option (right to buy)
Nov 19, 2021 Sell 20 000 Feldbaum Carl B Common Stock
Nov 19, 2021 Buy 20 000 Feldbaum Carl B Common Stock
Nov 15, 2021 Sell 44 184 Haley Patrick J. Common Stock
Show all Insider Trades
INSIDER POWER

0.717

Last 100 transactions
Buy: 1 481 300 | Sell: 2 066 049 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 17.01 7.41 %
16.66 5.16 %
16.44 3.78 %
Current price: 15.84
Support 15.73 -0.71 %
15.51 -2.09 %
15.15 -4.34 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 19.24 21.46 %
18.93 19.51 %
18.10 14.27 %
Current price 15.84
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Exelixis

Exelixis Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT